Claims for Patent: 7,625,875

Summary for Patent: 7,625,875

Title:	2\' and 3\'-nucleoside prodrugs for treating Flaviviridae infections
Abstract:	2\' and 3\'-Prodrugs of 1\', 2\', 3\' or 4\'-branched .beta.-D or .beta.-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
Inventor(s):	Gosselin; Gilles (Monpellier, FR), Storer; Richard (Folkstone, GB), LaColla; Paola (Cagliari, IT), Sommadossi; Jean-Pierre (Cambridge, MA)
Assignee:	Idenix Pharmaceuticals, Inc. (Cambridge, MA) Universita Degli Studi di Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR)
Application Number:	11/005,444
Patent Claims:	1. A method for the treatment of a Hepatitis C virus infection in a host, comprising administering to the host an effective amount of a compound of formula ##STR00077## or a pharmaceutically acceptable salt thereof wherein: Base is a purine; R.sup.1 is hydrogen, mono, di or triphosphate or a stabilized phosphate; R.sup.2 is an amino acid ester; and R.sup.6 is alkyl. 2. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination or alternation with a second anti-viral agent. 3. The method of claim 2, wherein the second anti-viral agent is selected from the group consisting of an interferon, ribavirin, an interleukin, a NS3 protease inhibitor, a HCV helicase inhibitor, a polymerase inhibitor, a nucleoside, an inhibitor of IRES-dependent translation, and a ribozyme. 4. The method of claim 3, wherein the second anti-viral agent is an interferon. 5. The method of claim 4, wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, and interferon gamma-1b. 6. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is in the form of a dosage unit. 7. The method of claim 6, wherein the dosage unit is a tablet or capsule. 8. The method of claim 1, wherein the host is a human. 9. The method of claim 1, wherein the compound is at least 85% by weight of the .beta.-D-isomer. 10. The method of claim 1, wherein the compound is at least 90% by weight of the .beta.-D-isomer. 11. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered in combination with a pharmaceutically acceptable carrier to form a composition. 12. The method of claim 11, wherein the pharmaceutically acceptable carrier is in a form that is suitable for oral delivery. 13. The method of claim 11, wherein the compound is in the form of a dosage unit. 14. The method of claim 13, wherein the dosage unit contains 50 to 1000 mg of the compound. 15. The method of claim 14, wherein said dosage unit is a tablet or capsule. 16. The method of claim 11, wherein the compound is at least 85% by weight of the .beta.-D-isomer. 17. The method of claim 11, wherein the pharmaceutically acceptable carrier is suitable for systemic, topical, parenteral, inhalant or intravenous delivery. 18. The method of claim 1, wherein R.sup.1 is a mono, di or triphosphate. 19. The method of claim 1, wherein R.sup.1 is hydrogen. 20. The method of claim 1, wherein R.sup.6 is methyl. 21. The method of claim 1, wherein the base is selected from the group consisting of N.sup.6-alkylpurine, N.sup.6-acylpurine, N.sup.6-benzylpurine, N.sup.6-vinylpurine, N.sup.6-acetylenic purine, N.sup.6-hydroxyalkylpurine, N.sup.6-alkylaminopurine, N.sup.6-thioalkylpurine, N.sup.2-alkylpurine, N.sup.2-alkyl-6-thiopurine and C.sup.5-hydroxyalkyl purine. 22. The method of claim 1 or 12, wherein the base is adenine. 23. The method of claim 1, wherein the base is guanine. 24. The method of claim 1, wherein R.sup.2 is an ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. 25. The method of claim 1, wherein R.sup.2 is an ester of a naturally occurring or synthetic .alpha., .beta., .gamma., or .delta. amino acid. 26. The method of claim 1, wherein R.sup.2 is an ester of an amino acid in the L configuration. 27. The method of claim 1, wherein R.sup.2 is an ester of valine. 28. The method of claim 19, wherein the host is a human. 29. The method of claim 1, wherein: R.sup.6 is methyl, ethyl or propyl. 30. The method of claim 29, wherein the base is selected from the group consisting of N.sup.6-alkylpurine, N.sup.6-acylpurine, N.sup.6-benzylpurine, N.sup.6-vinylpurine, N.sup.6-acetylenic purine, N.sup.6-hydroxyalkylpurine, N.sup.6-alkylaminopurine, N.sup.6-thioalkylpurine, N.sup.2-alkylpurine, N.sup.2-alkyl-6-thiopurine and C.sup.5-hydroxyalkyl purine. 31. The method of claim 29, wherein the base is adenine. 32. The method of claim 29, wherein the base is guanine. 33. The method of claim 29, wherein R.sup.2 is an ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. 34. The method of claim 29, wherein R.sup.2 is an ester of a naturally occurring or synthetic .alpha., .beta., .gamma., or .delta. amino acid. 35. The method of claim 29, wherein R.sup.2 is an ester of an amino acid in the L configuration. 36. The method of claim 29, wherein R.sup.2 is an ester of valine. 37. The method of claim 29 wherein the host is a human. 38. The method of claim 29, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination or alternation with a second anti-viral agent. 39. The method of claim 38 wherein the second anti-viral agent is selected from the group consisting of an interferon, ribavirin, an interleukin, an NS3 protease inhibitor, a HCV helicase inhibitor, a polymerase inhibitor, a nucleoside, and an inhibitor of IRES-dependent translation. 40. The method of claim 39, wherein the second anti-viral agent is an interferon. 41. The method of claim 38, wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, and interferon gamma-1b. 42. The method of claim 1, wherein the base is hypoxanthine. 43. The method of claim 1, wherein the base is 2,6-diaminopurine. 44. The method of claim 1, wherein the base is 6-chloropurine.

Details for Patent 7,625,875

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2022-06-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2022-06-28
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2022-06-28